Table 1.
Clinical characteristics of the study population
| Characteristics | Total | Patients survived | Patients died | P Value |
|---|---|---|---|---|
| No. of patients | N = 2174 | N = 1981 | N = 193 | |
| Age | 64.54 ± 10.57 | 63.96 ± 10.54 | 70.54 ± 8.83 | <0.001 |
| Gender, man, n (%) | 1713 (78.79%) | 1572 (79.35) | 141 (73.06) | 0.041 |
| Medical history | ||||
| Pre-hypertension, n (%) | 1183 (54.64) | 1072 (54.31) | 111 (58.12) | 0.313 |
| Pre-diabetes mellitus, n (%) | 470 (21.72) | 412 (20.88) | 58 (30.37) | 0.002 |
| Pre-heart failure, n (%) | 83 (5.3) | 60 (4.3) | 23 (12.2) | <0.001 |
| Pre-myocardial infarction, n (%) | 379 (23.9) | 329 (23.6) | 50 (26.3) | 0.475 |
| At admission | ||||
| HR, beats/min | 74.99 ± 26.09 | 74.51 ± 26.69 | 79.96 ± 18.05 | <0.001 |
| SBP, mm Hg | 130.51 ± 22.1 | 130.68 ± 21.52 | 128.79 ± 27.43 | 0.263 |
| DBP, mm Hg | 76.29 ± 12.8 | 76.52 ± 12.64 | 73.88 ± 14.11 | <0.001 |
| LVEF, % | 50.52 ± 24.62 | 50.55 ± 24.95 | 50.22 ± 19.41 | 0.896 |
| Risk assessment | ||||
| GRACE risk score | 92.95 ± 26.1 | 91.35 ± 25.64 | 109.44 ± 25.2 | <0.001 |
| TIMI classification | 4.58 ± 2.03 | 4.39 ± 1.94 | 5.94 ± 2.20 | <0.001 |
| Laboratory values | ||||
| Serum creatinine, μmol/L | 94.44 ± 51.3 | 92.69 ± 47.87 | 112.37 ± 76 | <0.001 |
| Blood glucose, mmol/L | 7.17 ± 3.3 | 7.03 ± 3.11 | 8.59 ± 4.6 | <0.001 |
| Total cholesterol, mmol/L | 4.13 ± 1.11 | 4.13 ± 1.1 | 4.09 ± 1.2 | 0.602 |
| WBC, n × 109/L | 7.92 ± 5.66 | 7.79 ± 5.75 | 9.23 ± 4.43 | <0.001 |
| RBC, n × 1012/L | 4.45 ± 1.11 | 4.47 ± 1.15 | 4.16 ± 0.65 | <0.001 |
| Hemoglobin, g/L | 134.22 ± 35.39 | 135.17 ± 36.42 | 124.42 ± 19.89 | <0.001 |
| Platelets, n × 109/L | 162.28 ± 61.05 | 161.79 ± 60.75 | 167.33 ± 63.95 | 0.229 |
| AST, U/L | 56.91 ± 102.95 | 52.55 ± 81.82 | 102.8 ± 222.7 | <0.001 |
| Serum K+, mmol/L | 3.96 ± 0.47 | 3.96 ± 0.45 | 4 ± 0.62 | 0.261 |
| Serum Ca2+, mmol/L | 2.32 ± 4.4 | 2.34 ± 4.61 | 2.16 ± 0.18 | 0.619 |
| Fibrinogen, g/L | 3.83 ± 11.22 | 3.8 ± 11.46 | 4.18 ± 8.23 | 0.679 |
| Discharge medications | ||||
| Aspirin, n (%) | 2005 (94.18%) | 1865 (96.68%) | 140 (70.0%) | <0.001 |
| Clopidogrel, n (%) | 2002 (94.03%) | 1854 (96.11%) | 148 (74.0%) | <0.001 |
| ACEI/ARBs, n (%) | 1228 (57.73%) | 1140 (59.16%) | 88 (44.0%) | <0.001 |
| Beta-blockers, n (%) | 1434 (67.45%) | 1340 (69.57%) | 94 (47.0%) | <0.001 |
| Statins, n (%) | 1949 (91.55%) | 1807 (93.68%) | 142 (71.0%) | <0.001 |
Data are expressed as mean ± SD or counts and percentages, as appropriate
HR heart rate, SBP systolic blood pressures, DBP diastolic blood pressure, LVEF left ventricular ejection fraction, GRACE Global Registry of Acute Coronary Events, TIMI thrombolysis in myocardial infarction, WBC white blood cell, RBC red blood cell, AST aspartate transaminase, ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin II receptor blockers